FDA Agrees to Review CTI App

Luke Timmerman8/24/09

Cell Therapeutics, the Seattle-based developer of cancer drugs, said today that the FDA has agreed to review the company’s application to market pixantrone for non-Hodgkin’s lymphoma in the U.S. The company (NASDAQ: CTIC) is seeking an expedited six-month review for the drug, which is sometimes granted for treatments with life-saving potential. The FDA will decide on its deadline for reviewing the Cell Therapeutics application by Sept. 4, the company said. The treatment, a form of anthracycline chemotherapy, was designed to be less toxic to the heart than other drugs in its class.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.